| Literature DB >> 28212612 |
Maria Paula Barbieri D'Elia1, Marcela Calixto Brandão2, Bruna Ribeiro de Andrade Ramos2, Márcia Guimarães da Silva2, Luciane Donida Bartoli Miot1, Sidney Emanuel Batista Dos Santos3, Hélio Amante Miot4.
Abstract
BACKGROUND: Melasma is a chronic acquired focal hypermelanosis affecting photoexposed areas, especially for women during fertile age. Several factors contribute to its development: sun exposure, sex steroids, medicines, and family history. Melanic pigmentation pathway discloses several SNPs in different populations. Here, we evaluated the association between genetic ancestry and facial melasma.Entities:
Keywords: Ancestry; Contraceptives; Gonadal steroid hormones; Hormones; INDEL; Melanosis; Melasma; Oral contraceptives; Pigmentation; Pigmentation disorders; Pregnancy; Skin pigmentation; Ultraviolet rays
Mesh:
Substances:
Year: 2017 PMID: 28212612 PMCID: PMC5316149 DOI: 10.1186/s12881-017-0378-7
Source DB: PubMed Journal: BMC Med Genet ISSN: 1471-2350 Impact factor: 2.103
Clinical and demographic data for patients with melasma
| Age of melasma onset (years)a | 27.2 (8.3) |
| Reported trigger factor − | |
| Pregnancy | 48 (40) |
| Sun exposure | 44 (37) |
| HC | 26 (22) |
| HRT | 2 (2) |
| Cosmetics/Treatments | 7 (6) |
| Stressful events | 3 (3) |
| Others | 6 (5) |
| Affected facial site − | |
| Zygomatic | 60 (50) |
| Frontal | 48 (40) |
| Upper lip | 44 (37) |
| Temporal | 39 (33) |
| Mentonian | 25 (21) |
| Mandibular | 22 (18) |
| Parotid | 20 (17) |
| Nasal | 19 (16) |
| Glabelar | 15 (13) |
| Affected facial sitesb | 3 (2–4) |
Abbreviations: HC hormonal oral contraception, HRT hormonal replacement therapy
amean (st deviation)
bmedian (p25–p75)
Demographic and genetic ancestry data from groups
| Variables | Melasma | Controls |
|
| ||
|---|---|---|---|---|---|---|
| Odds Ratio (CI 95%) |
| Odds Ratio (CI 95%) |
| |||
| Age (years)a | 39.0 (8.2) | 39.0 (9.7) | – | – | 0.99 (0.95–1.02) | 0.44 |
| Skin phototype- | 0.09 | 0.13 | ||||
| II | 18 (15) | 30 (25) | 1.00 (–) | 1.00 (–) | ||
| III | 42 (35) | 45 (38) | 1.56 (0.76–3.20) | 1.32 (0.57–3.02) | ||
| IV | 46 (39) | 30 (25) | 2.56 (1.22–5.38) | 1.40 (0.58–3.39) | ||
| V | 13 (11) | 14 (12) | 1.55 (0.60–4.02) | 0.39 (0.11–1.40) | ||
| Education level- | <0.01 | 0.01 | ||||
| Elementary-Middle school | 39 (33) | 14 (12) | 4.67 (2.24–9.73) | 4.04 (1.62–10.11) | ||
| High school | 43 (36) | 43 (36) | 1.68 (0.93–3.01) | 1.71 (0.85–3.44) | ||
| College | 37 (31) | 62 (52) | 1.00 (–) | 1.00 (–) | ||
| Family with melasma (first degree)-N (%) | 67 (56) | 27 (24) | 3.10 (1.11–8.70) | 0.03 | 3.04 (1.56–5.94) | <0.01 |
| Age of menarche (years)a | 12.8 (1.8) | 12.7 (1.8) | 1.01 (0.88–1.16) | 0.92 | – | – |
| Time using hormonal contraception (years)b | 10 (3–15) | 5 (1–12) | 1.03 (0.98–1.07) | 0.13 | 1.02 (0.98–1.07) | 0.33 |
| Daily regular sun exposition- | 42 (44) | 24 (27) | 2.15 (1.16–3.99) | 0.02 | 1.09 (0.57–2.10) | 0.80 |
| Pregnancy history- | 92 (77) | 77 (65) | 1.86 (1.05–3.29) | 0.03 | 1.50 (0.69–3.29) | 0.31 |
| Psycotropic drugs (regular use)- | ||||||
| Antidepressant | 28 (24) | 18 (15) | 1.73 (0.90–3.33) | 0.10 | 2.96 (0.37–24.03) | 0.31 |
| Anxiolytic | 11 (9) | 5 (4) | 2.32 (0.78–6.90) | 0.12 | – | – |
| Genetic ancestry (%)b | ||||||
| European component | 77 (64–89) | 82 (69–90) | 0.98 (0.97–0.99) | 0.04 | – | – |
| Amerindian component | 7 (4–14) | 7 (4–14) | 1.00 (0.97–1.02) | 0.72 | – | – |
| African component | 10 (4–21) | 6 (4–16) | 1.03 (1.01–1.05) | <0.01 | 1.04 (1.01–1.07) | <0.01 |
| Interactions | ||||||
| Antidepressanta Family with melasma | 6.15 (1.13–33.37) | <0.01 | ||||
| Antidepressanta Pregnancy history | 0.14 (0.01–1.35) | 0.09 | ||||
p (overall model) < 0.01; Hosmer-Lemeshow test: p = 0.98; Correct classification: 72%; R2 (Nagelkerke): 0.31
amean (st deviation)
bmedian (p25–p75)
Fig. 1Ternary plot of group genetic ancestral composition